Clinically, breast cancer patients with cardiac dysfunction and arrhythmias are often monitored and intervened during the treatment, such as application of angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers. The gene discussed is ACE; the disease is Arrhythmia.